Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
As with all non-injectable MT-II formats, bioavailability is expected to be lower than subcutaneous injection this difference in systemic exposure is itself of research interest when comparing mucosal and injectable delivery mechanics
That said, competition is coming: Pfizers cotadutide (dual agonist) is in late-stage trials, and if approved, could eat into Lillys share
Since their launch, Ozempic and Wegovy have dominated the headlines
Some patients have reported requiring gastric bypass surgery due to severe medication-induced gastroparesis
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P)
How to get weight loss medication
